OBSERVED REDUCTION OF HEALTHCARE UTILIZATION AFTER OMALIZUMAB INITIATION AMONG PATIENTS WITH PERSISTENT ASTHMA FOLLOWED IN CANADIAN CLINICAL SETTINGS.
Author(s)
Yang WH1, Gagnon R2, Psaradellis E3, Rampakakis E3, Stril J4, Chehab S4
1Ottawa Allergy Research Corporation, Ottawa, ON, Canada, 2Centre hospitalier Universitaire de Québec, Université Laval, Quebec City, QC, Canada, 3JSS Medical Research, Montreal, QC, Canada, 4Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada
OBJECTIVES: The primary objective was to evaluate the health care utilization (HCU) following omalizumab (OMA) initiation as assessed by the reduction in number of hospitalizations, emergency room (ER) visits, and oral corticosteroid (OCS) use in patients covered in Ontario. The number of night awakenings was an exploratory endpoint. METHODS: This study is a retrospective, pre-post cohort, observational study. The data was collected from the patient support program. Individuals were enrolled to the Ontario Trillium Drug Program and had access to OMA through Exceptional Access Program (EAP). Individuals were identified and their OMA EAP claims for the relevant period. The data extract included patients with an enrollment form receipt date greater than July 17th 2013 or a reactivation form receipt date greater than July 17th 2013. The end date of data collection was May 5th, 2016 RESULTS: CONCLUSIONS: There was an observed reduction in the number of hospitalizations, ER visits, and high-dose OCS courses post-omalizumab use in patients with severe uncontrolled asthma in a Canadian real-world setting. The results are consistent with outcomes observed in previous large real-world trials such as the eXperience registry.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PRS67
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Respiratory-Related Disorders